Histamine H 3 receptor blockade alleviates neuropathic pain through the regulation of glial cells activation.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model and in vitro laboratory study without human participants.
PubMed 39818100 · doi:10.1016/j.biopha.2025.117850
What was done
Researchers evaluated the analgesic and anti-inflammatory effects of E-98, a novel histamine H3 receptor (H3R) antagonist/inverse agonist, in male mice subjected to sciatic nerve chronic constriction injury. They tested single intraperitoneal doses (1, 5, 10, and 20 mg/kg) and intrathecal injections (10, 30, and 60 µg/5 µL) on mechanical (von Frey) and thermal (cold plate, tail flick) pain thresholds. They also tested chronic intraperitoneal administration (10 mg/kg) on spinal glial activation, assessed 10 µM E-98 on primary microglial and astroglial cell cultures, and measured H3R co-localization and IL-6 levels.
What was found
The abstract reports no exact numerical values or effect sizes. E-98 attenuated mechanical and thermal nociceptive responses in a dose- and time-dependent manner. This behavioral effect was accompanied by decreased microglial activation and increased astroglia activation in the lumbar spinal cord. In primary microglial and astroglial cell cultures, E-98 decreased pro-inflammatory IL-6 levels, and H3R was observed co-localizing with spinal neurons, microglia, and astrocytes.
Why it matters
Targeting histamine H3 receptors may offer a dual neuro-glial mechanism for developing analgesics to manage neuropathic pain.
Limits
The study was conducted entirely in rodent models and cell cultures, which cannot establish human clinical efficacy or safety. The abstract provides no exact quantitative data, effect sizes, or sample sizes (n). Only male mice were tested, precluding analysis of sex-specific pain and inflammatory mechanisms.
Cited by
- supports Histamine and glutamate signaling pathways are directly involved in the cell signaling of chronic pain.